Hypothesis

Senescent cells, particularly p16^hi fibroblasts, act as chaperones that fine‑tune eosinophil recruitment and function during skeletal muscle regeneration by secreting a dose‑dependent SASP chemokine profile (e.g., CCL11/eotaxin) that attracts eosinophils to the injury site; eosinophil‑derived IL‑4 then activates fibro/adipogenic progenitors (FAPs) to promote regenerative matrix deposition, while excess eosinophils driven by loss of senescent‑cell restraint promote fibrosis. Consequently, indiscriminate senolytic ablation disrupts this eosinophil‑senescent cell axis, leading to either impaired regeneration or pathological fibrosis depending on the timing and magnitude of chemokine dysregulation.

Mechanistic Rationale

• Eosinophils are essential for muscle repair through IL‑4 secretion that activates FAPs, a process shown to be critical for regeneration [eosinophils essential for skeletal muscle regeneration].
• Young eosinophil transfers reverse age‑related inflammation and improve physical fitness, indicating that eosinophil function can be therapeutically harnessed [young eosinophil transfers].
• Both eosinophil deficiency and eosinophil excess impair muscle healing: deficiency blocks regeneration, whereas excess drives fibrosis via TGF‑β and alternative activation pathways [eosinophil dosage effect]
• Senescent fibroblasts early after injury express developmental and morphogenetic programs, suggesting a regenerative capacity beyond mere damage signaling [young senescent fibroblasts].
• SASP includes chemokines such as CCL11 (eotaxin), CCL7, and CXCL1 that are potent eosinophil chemoattractants; their expression is known to be heterogeneous and can be tuned by senescent cell burden and microenvironmental cues.
• Senolytics clear senescent cells and reduce pro‑inflammatory mediators, improving transplant outcomes and age‑related inflammation [senolytics benefits], yet they may also ablatively remove the very cells that calibrate eosinophil numbers.

Novel insight: Senescent fibroblasts secrete a gradient of CCL11 that creates a chemotactic niche; low‑grade SASP yields eosinophil numbers sufficient for IL‑4‑mediated FAP activation, whereas high‑grade SASP (or SASP loss after senolytic clearance) skews eosinophil recruitment toward either insufficient or supraphysiological levels, tipping the balance between regeneration and fibrosis.

Experimental Design

1. Model: Induce acute skeletal muscle injury (cardiotoxin) in young and aged mice carrying a p16‑3MR reporter to visualize and pharmacologically ablate senescent cells with ganciclovir (GCV).
2. Groups: (a) Injury + vehicle, (b) Injury + GCV (senolytic), (c) Injury + GCV + recombinant CCL11 (low dose), (d) Injury + GCV + eosinophil transfer (sorted from young donors), (e) Injury + GCV + eosinophil depletion (anti‑Siglec‑F antibody).
3. Readouts (day 3–14 post‑injury):
   • Flow cytometry and immunofluorescence for eosinophil infiltration (Siglec‑F^+ CCR3^+).
   • SASP chemokine quantification in tissue homogenates (CCL11, CCL7) via ELISA or Luminex.
   • FAP activation (PDGFRα^+ IL‑4R^+ pSTAT6^+).
   • Regeneration metrics: centrally nucleated fibers, MyoD^+ myoblasts, muscle force (in situ tetanic torque).
   • Fibrosis assessment: Sirius Red staining, hydroxyproline content, collagen I/III mRNA.
   • Physical function: grip strength, treadmill endurance.
4. Controls: Sham‑injured mice; senescence‑negative (p16^-^) littermates; isotype antibodies.

Predictions and Falsifiability

• If the hypothesis is true:
  • Senescent cell ablation (GCV) will reduce eosinophil numbers in the injury milieu compared with vehicle, correlating with diminished CCL11 levels.
  • This eosinophil deficit will impair regeneration (fewer central nuclei, lower force) and can be rescued by exogenous CCL11 or eosinophil transfer.
  • Conversely, excessive eosinophil accumulation (e.g., in aged mice with heightened SASP) will exacerbate fibrosis; senolytic treatment in this context will normalize eosinophil influx and reduce collagen deposition.
  • Eosinophil depletion in the presence of intact senescent cells will phenocopy the regenerative defect seen after senolytic ablation, confirming eosinophils as downstream effectors.
• Falsifying outcomes:
  • Senolytic clearance does not alter eosinophil infiltration or CCL11 levels, yet regeneration changes.
  • Eosinophil numbers remain unchanged after senolysis, and neither CCL11 supplementation nor eosinophil transfer rescues the regenerative deficit.
  • Fibrosis outcomes are unchanged regardless of eosinophil manipulation, indicating that eosinophils are not the critical mediators of the senescent‑cell‑dependent repair phenotype.

By directly linking senescent‑cell‑derived chemokines to eosinophil‑driven FAP activation, this hypothesis provides a testable framework that reconciles the paradoxical benefits and risks of senolysis and reveals a potential therapeutic window where modulating the senescent‑eosinophil axis—rather than ablating senescent cells outright—could enhance tissue regeneration while limiting fibrosis.